Sign In
Buy NTLA
$13.02
-0.110 (-0.84%)
At Close: Jun 03, 2026
Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week
09:57am, Friday, 15'th Oct 2021
A key gene-editing readout had Cathie Wood shuffling her portfolio.
Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology
07:01am, Wednesday, 13'th Oct 2021
CAMBRIDGE, Mass. and PARIS, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics us
Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology
07:00am, Wednesday, 13'th Oct 2021
Intellia Therapeutics and SparingVision Announce S trategic C ollaboration to D evelop N ovel O cular T herapies U sing CRISPR /Cas9 T echnology
CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/
NTLA Stock: Why It Increased Today
11:42am, Thursday, 07'th Oct 2021
The stock price of Intellia Therapeutics Inc (NASDAQ: NTLA) increased over 5% during intraday trading today. This is why it happened.
Intellia To Test Second CRISPR Therapeutic In Hereditary Angioedema Patients
08:29am, Wednesday, 06'th Oct 2021
The New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) has signed off Intellia Therapeutics Inc's (NASDAQ: NTLA) Phase 1/2 study of NTLA-2002 in hereditary angioedema (HAE). NTLA-
Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema
07:30am, Wednesday, 06'th Oct 2021
CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/
Intellia Therapeutics to Present at Chardan's 5th Annual Genetic Medicines Conference
07:30am, Monday, 27'th Sep 2021
CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR
Intellia To Test CRISPR-Engineered TCR-T Cell Candidate In Acute Myeloid Leukemia Patients
10:10am, Thursday, 16'th Sep 2021
The FDA has signed off Intellia Therapeutics Inc's (NASDAQ: NTLA) investigational new drug (IND) application for NTLA-5001. Related Content: Intellia Shares Shoot Higher On Promising Biomarker D
CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR
7 Gene Editing Stocks Promising to Change our DNA
12:45pm, Wednesday, 15'th Sep 2021
Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market. The post 7 Gene Editing Stocks Promising to Change our DNA appeared
Forget About the Genomic Revolution, the Proteomic Revolution Is Coming
05:30pm, Friday, 03'rd Sep 2021
Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing. The post Forget About the Genomic R
Forget About the Genomic Revolution, the Proteomic Revolution Is Coming
07:30am, Friday, 03'rd Sep 2021
Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing. The post Forget About the Genomic R
Intellia's Bold Bet Pays Off, Justifying Its Valuation
12:55am, Friday, 03'rd Sep 2021
Intellia's Bold Bet Pays Off, Justifying Its Valuation
Intellia Therapeutics to Present at September Healthcare Investor Conferences
07:30am, Tuesday, 31'st Aug 2021
CAMBRIDGE, Mass., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/
